Simulation Result 1: $C \sim Exp(0.2)$

Yi 2023-02-20

Table 1: Summary of the estimated SAUC for Biomarker when the true censoring is distributed as Exp(0.2).

			p = 0.7	p = 0.5	p = 0.3
Patients	N	Method	Median (Q1, Q3)	Median (Q1, Q3)	Median (Q1, Q3)
50-150	20	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	74.97 (73.45, 76.48) 76.30 (74.33, 78.03) 75.73 (73.47, 77.88)	74.78 (73.43, 75.97) 76.51 (74.57, 78.51) 75.23 (73.02, 77.68)	74.68 (73.69, 75.66) 77.03 (75.15, 79.14) 74.70 (72.10, 77.02)
	30	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	74.79 (73.58, 75.95) 75.89 (74.27, 77.41) 75.38 (73.72, 77.27)	74.59 (73.54, 75.58) 76.22 (74.54, 77.85) 74.80 (72.84, 76.69)	74.52 (73.76, 75.32) 77.01 (75.42, 78.57) 74.48 (72.28, 76.40)
	50	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	74.68 (73.78, 75.58) 75.76 (74.67, 76.93) 75.19 (73.68, 76.58)	74.60 (73.73, 75.38) 76.27 (75.06, 77.32) 74.63 (73.16, 76.16)	74.52 (73.85, 75.12) 76.79 (75.60, 78.07) 74.21 (72.42, 76.02)
	100	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	74.54 (73.87, 75.17) 75.53 (74.75, 76.31) 74.88 (73.85, 76.11)	74.53 (73.96, 75.05) 76.13 (75.32, 76.94) 74.63 (73.50, 76.13)	74.42 (73.93, 74.82) 76.80 (75.93, 77.54) 74.20 (72.92, 75.48)
50-300	20	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	75.87 (74.66, 77.07) 76.73 (75.22, 78.36) 76.52 (74.68, 78.10)	75.73 (74.79, 76.82) 77.29 (75.65, 78.87) 76.35 (74.51, 77.90)	75.73 (74.99, 76.53) 77.90 (76.18, 79.45) 75.82 (73.93, 77.37)
	30	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	75.85 (74.85, 76.88) 76.77 (75.43, 77.98) 76.47 (75.03, 77.75)	75.68 (74.84, 76.53) 77.02 (75.77, 78.34) 76.02 (74.59, 77.53)	75.69 (75.03, 76.33) 77.79 (76.19, 79.14) 75.79 (74.15, 77.29)
	50	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	75.76 (74.96, 76.51) 76.51 (75.48, 77.45) 76.12 (75.04, 77.33)	75.61 (75.04, 76.22) 76.75 (75.81, 77.69) 75.79 (74.79, 76.96)	75.59 (75.08, 76.07) 77.40 (76.36, 78.48) 75.57 (74.42, 76.76)
	100	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	74.54 (73.87, 75.17) 75.53 (74.75, 76.31) 74.88 (73.85, 76.11)	74.53 (73.96, 75.05) 76.13 (75.32, 76.94) 74.63 (73.50, 76.13)	74.42 (73.93, 74.82) 76.80 (75.93, 77.54) 74.20 (72.92, 75.48)

Median with 25th and 75th empirical quartiles (Q1, Q3) of the SAUC at t=2 are reported. N denotes the number of the published studies. Proposed denotes the proposed sensitivity analysis method; HZ_P denotes the HZ model using the population (published and unpublished) studies; HZ_O denotes the HZ model using the observed (published) studies. CR denotes the proportion of convergence among 1000 repetition All the entries are multiplied by 100.

Table 2: Summary of the estimated SAUC for Biomarker when the true censoring is distributed as Exp(0.2).

			p = 0.7	p = 0.5	p = 0.3
Patients	N	Method	Median (Q1, Q3)	Median (Q1, Q3)	Median (Q1, Q3)
50-150	20	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.63 (56.65, 58.68) 59.42 (58.40, 60.65) 58.74 (57.45, 59.85)	57.74 (56.91, 58.64) 60.69 (59.44, 61.90) 59.17 (57.54, 60.66)	57.68 (57.07, 58.42) 61.96 (60.72, 63.20) 59.64 (57.22, 61.72)
	30	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.79 (56.95, 58.56) 59.64 (58.67, 60.63) 58.79 (57.67, 59.81)	57.77 (57.03, 58.42) 60.64 (59.74, 61.60) 59.29 (57.69, 60.63)	57.77 (57.23, 58.27) 61.89 (60.92, 62.90) 60.20 (57.32, 61.83)
	50	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.74 (57.09, 58.33) 59.59 (58.88, 60.38) 58.79 (57.76, 59.65)	57.73 (57.16, 58.24) 60.67 (59.98, 61.41) 59.48 (57.61, 60.63)	57.73 (57.32, 58.15) 62.00 (61.22, 62.73) 60.56 (57.09, 61.98)
	100	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.71 (57.31, 58.19) 59.63 (59.13, 60.14) 58.99 (57.97, 59.72)	57.72 (57.36, 58.10) 60.68 (60.14, 61.21) 59.69 (57.54, 60.69)	57.74 (57.44, 58.02) 62.00 (61.44, 62.53) 61.43 (57.61, 62.17)
50-300	20	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.91 (57.09, 58.64) 59.27 (58.30, 60.07) 58.38 (57.46, 59.23)	57.90 (57.31, 58.54) 60.07 (59.24, 60.89) 58.35 (57.17, 59.43)	57.93 (57.50, 58.38) 61.06 (60.11, 61.99) 57.90 (56.53, 59.14)
	30	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.95 (57.24, 58.59) 59.34 (58.57, 60.05) 58.32 (57.47, 59.11)	57.87 (57.37, 58.37) 60.08 (59.44, 60.82) 58.09 (57.19, 59.03)	57.92 (57.52, 58.33) 61.07 (60.30, 61.81) 57.60 (56.63, 58.77)
	50	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.95 (57.47, 58.40) 59.35 (58.82, 59.91) 58.22 (57.61, 58.89)	57.95 (57.50, 58.35) 60.11 (59.55, 60.68) 57.98 (57.18, 58.74)	57.93 (57.60, 58.23) 61.10 (60.50, 61.64) 57.45 (56.64, 58.30)
	100	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.71 (57.31, 58.19) 59.63 (59.13, 60.14) 58.99 (57.97, 59.72)	57.72 (57.36, 58.10) 60.68 (60.14, 61.21) 59.69 (57.54, 60.69)	57.74 (57.44, 58.02) 62.00 (61.44, 62.53) 61.43 (57.61, 62.17)

Median with 25th and 75th empirical quartiles (Q1, Q3) of the SAUC at t=2 are reported. N denotes the number of the published studies. Proposed denotes the proposed sensitivity analysis method; HZ_P denotes the HZ model using the population (published and unpublished) studies; HZ_O denotes the HZ model using the observed (published) studies. CR denotes the proportion of convergence among 1000 repetition All the entries are multiplied by 100.

Table 3: Summary of the estimated SAUC for Biomarker when the true censoring is distributed as U(1,4), but a misspecified exponential distribution is fitted.

			p = 0.7	p = 0.5	p = 0.3
Patients	N	Method	Median (Q1, Q3)	Median (Q1, Q3)	Median (Q1, Q3)
50-150	20	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	75.07 (73.54, 76.47) 76.29 (74.13, 78.10) 76.47 (74.27, 78.62)	74.95 (73.75, 76.05) 76.81 (74.77, 78.67) 75.88 (73.57, 77.99)	75.01 (74.04, 75.88) 77.66 (75.62, 79.53) 75.18 (72.99, 77.49)
	30	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	75.05 (73.89, 76.20) 76.24 (74.85, 77.58) 76.27 (74.64, 78.23)	74.92 (73.98, 75.91) 76.76 (75.36, 78.17) 75.76 (73.92, 77.63)	74.88 (74.06, 75.66) 77.27 (75.80, 78.85) 74.85 (72.72, 76.92)
	50	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	74.94 (73.92, 75.78) 75.95 (74.84, 77.03) 75.94 (74.50, 77.38)	74.81 (74.04, 75.59) 76.31 (75.05, 77.39) 75.09 (73.51, 76.59)	74.80 (74.21, 75.36) 76.98 (75.87, 78.08) 74.43 (72.73, 76.17)
	100	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	74.81 (74.14, 75.41) 75.81 (74.98, 76.59) 75.54 (74.48, 76.72)	74.77 (74.27, 75.28) 76.32 (75.54, 77.10) 74.98 (73.85, 76.25)	74.76 (74.30, 75.19) 77.03 (76.18, 77.76) 74.34 (73.01, 75.60)
50-300	20	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	76.22 (75.28, 77.32) 77.13 (75.76, 78.71) 77.43 (75.14, 79.55)	76.13 (75.17, 77.04) 77.74 (76.27, 79.15) 76.91 (74.83, 78.65)	75.97 (75.20, 76.64) 78.24 (76.68, 79.81) 76.05 (74.26, 77.71)
	30	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	76.08 (75.08, 76.99) 76.99 (75.62, 78.19) 76.96 (75.11, 78.73)	75.98 (75.14, 76.71) 77.50 (76.27, 78.79) 76.55 (74.86, 78.17)	75.82 (75.30, 76.36) 78.15 (76.64, 79.48) 76.04 (74.49, 77.57)
	50	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	75.97 (75.23, 76.61) 76.72 (75.82, 77.63) 76.63 (75.38, 78.08)	75.93 (75.36, 76.50) 77.31 (76.24, 78.24) 76.44 (75.08, 77.62)	75.82 (75.34, 76.26) 77.80 (76.50, 79.06) 75.64 (74.52, 76.95)
	100	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	74.81 (74.14, 75.41) 75.81 (74.98, 76.59) 75.54 (74.48, 76.72)	74.77 (74.27, 75.28) 76.32 (75.54, 77.10) 74.98 (73.85, 76.25)	74.76 (74.30, 75.19) 77.03 (76.18, 77.76) 74.34 (73.01, 75.60)

Median with 25th and 75th empirical quartiles (Q1, Q3) of the SAUC at t=2 are reported. N denotes the number of the published studies. Proposed denotes the proposed sensitivity analysis method; HZ_P denotes the HZ model using the population (published and unpublished) studies; HZ_O denotes the HZ model using the observed (published) studies. CR denotes the proportion of convergence among 1000 repetition All the entries are multiplied by 100.

Table 4: Summary of the estimated SAUC for Biomarker when the true censoring is distributed as U(1,4), but a misspecified exponential distribution is fitted.

			p = 0.7	p = 0.5	p = 0.3
Patients	N	Method	Median (Q1, Q3)	Median (Q1, Q3)	Median (Q1, Q3)
50-150	20	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.78 (56.84, 58.68) 59.82 (58.64, 60.88) 58.71 (57.60, 59.84)	57.80 (56.96, 58.65) 61.09 (59.90, 62.16) 58.83 (57.39, 60.22)	57.79 (57.16, 58.39) 62.47 (61.29, 63.67) 58.44 (56.70, 60.35)
	30	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.72 (56.99, 58.42) 59.79 (58.96, 60.71) 58.58 (57.60, 59.57)	57.79 (57.13, 58.40) 61.08 (60.17, 61.93) 58.61 (57.28, 59.96)	57.82 (57.29, 58.32) 62.52 (61.65, 63.44) 58.04 (56.56, 60.13)
	50	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.90 (57.27, 58.43) 59.97 (59.30, 60.62) 58.51 (57.77, 59.39)	57.84 (57.34, 58.29) 61.10 (60.49, 61.76) 58.32 (57.39, 59.55)	57.79 (57.37, 58.16) 62.43 (61.72, 63.12) 57.70 (56.48, 59.24)
	100	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.82 (57.37, 58.21) 59.85 (59.38, 60.32) 58.36 (57.69, 59.07)	57.80 (57.47, 58.17) 61.12 (60.64, 61.59) 57.91 (57.24, 58.84)	57.81 (57.54, 58.08) 62.45 (61.98, 62.94) 57.26 (56.42, 58.31)
50-300	20	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	58.01 (57.28, 58.74) 59.52 (58.68, 60.39) 58.40 (57.45, 59.34)	57.90 (57.33, 58.50) 60.33 (59.49, 61.11) 58.03 (57.16, 58.98)	58.00 (57.50, 58.45) 61.40 (60.52, 62.26) 57.73 (56.65, 58.71)
	30	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.97 (57.37, 58.56) 59.50 (58.84, 60.14) 58.23 (57.47, 58.98)	57.96 (57.43, 58.41) 60.41 (59.66, 61.00) 58.04 (57.23, 58.74)	57.91 (57.58, 58.30) 61.33 (60.65, 61.98) 57.56 (56.65, 58.38)
	50	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.94 (57.50, 58.43) 59.47 (58.97, 59.99) 58.15 (57.58, 58.79)	57.93 (57.51, 58.30) 60.35 (59.83, 60.86) 57.87 (57.19, 58.53)	57.94 (57.66, 58.22) 61.36 (60.79, 61.83) 57.42 (56.64, 58.12)
	100	$egin{aligned} & \operatorname{HZ}_P \ & \operatorname{HZ}_O \ & \operatorname{Prop} \end{aligned}$	57.82 (57.37, 58.21) 59.85 (59.38, 60.32) 58.36 (57.69, 59.07)	57.80 (57.47, 58.17) 61.12 (60.64, 61.59) 57.91 (57.24, 58.84)	57.81 (57.54, 58.08) 62.45 (61.98, 62.94) 57.26 (56.42, 58.31)

Median with 25th and 75th empirical quartiles (Q1, Q3) of the SAUC at t=2 are reported. N denotes the number of the published studies. Proposed denotes the proposed sensitivity analysis method; HZ_P denotes the HZ model using the population (published and unpublished) studies; HZ_O denotes the HZ model using the observed (published) studies. CR denotes the proportion of convergence among 1000 repetition All the entries are multiplied by 100.